CCM
HOWL icon

CAAS Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

CAAS Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-62,599
Closed -$256K – 863
2022
Q3 		$256K Hold
62,599
– – 0.01% 608
2022
Q2 		$256K Sell
62,599
-38,996
-38% -$178K 0.01% 632
2022
Q1 		$447K Sell
101,595
-61,004
-38% -$427K 0.02% 405
2021
Q4 		$1.94M Hold
162,599
– – 0.05% 326
2021
Q3 		$2.79M Buy
162,599
+62,599
+63% +$1.07M 0.06% 299
2021
Q2 		$1.74M Buy
+100,000
New +$1.37M 0.03% 425

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

CAAS Capital Management's HOWL Position: Q4 2022 in Review

CAAS Capital Management sold out of Werewolf Therapeutics (HOWL) in Q4 2022, closing a stake of 62,599 shares — an estimated $256K sold.

CAAS Capital Management first reported a position in HOWL in Q2 2021 and held it in 6 quarters. The position peaked at $2.79M in Q3 2021. 39 funds tracked by Wall St. Rank hold HOWL as of Q4 2022.

  • CAAS Capital Management reported no remaining Werewolf Therapeutics position as of Q4 2022 after selling out during the quarter.
  • CAAS Capital Management sold 62,599 Werewolf Therapeutics shares in Q4 2022, an estimated $256K.
  • CAAS Capital Management first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 6 quarters.
  • CAAS Capital Management's Werewolf Therapeutics position peaked at $2.79M in Q3 2021.
  • 39 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2022.

Based on CAAS Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.